Palantir stock keeps NHS contract through 2029 as UK plans tender
Published on 11/19/2026 at 14:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPalantir keeps NHS contract
- The UK government will keep Palantir's NHS Federated Data Platform contract in place until March 2029.
- The existing arrangement has a maximum value of 330 million pounds and includes other suppliers.
- A replacement procurement is expected to begin in 2027, leaving Palantir exposed to a future competitive tender.
On November 16, the UK government decided to keep Palantir's NHS Federated Data Platform contract in place until March 2029, the BBC reported on November 17. Ministers chose not to use an earlier break clause that could have ended the arrangement in February 2027.
Palantir stock traded at 146.32 euros on Lang & Schwarz at 14:01 CET on Thursday, November 19, 2026.
Contract runs while replacement is prepared
The NHS Federated Data Platform connects information held by hospitals and other health organisations in England. The current deal began in 2024 and has a maximum value of 330 million pounds. The contract includes other suppliers alongside Palantir, so the full ceiling is not attributable to Palantir alone.
Health minister James Frith said the government would preserve continuity of care while preparing a successor arrangement. The Department of Health and Social Care plans market engagement from January 2027, with a formal procurement process expected in the second half of that year.
The decision gives Palantir additional operating time in a high-profile public-sector account, but it does not secure the successor contract. The government intends to invite UK and international providers to compete, with interoperability, resilience and common standards among the stated priorities.
Investor focus shifts to the next tender
For investors, the immediate significance is continuity rather than a new award. Palantir retains access to an important reference customer for more than two years, while the later tender creates a separate competitive test for its position in UK health technology.
Palantir UK welcomed the decision and said its work was helping deliver more operations, speed up hospital discharge and reduce waiting times for cancer diagnoses, according to the BBC. Government officials and critics remain focused on supplier dependence, patient-data governance and the transition to a replacement platform.
The procurement timetable is the next material milestone. Market engagement is due to start in January 2027, followed by a formal tender in the second half of the year; the existing contract is scheduled to end in March 2029.
The broader US market can be followed through the S&P 500.
More news and analyses on Palantir stock
Palantir Technologies
- Company: Palantir Technologies
- ISIN: US69608A1088
- Market quote: 146.32 euros on Lang & Schwarz, November 19, 2026, 14:01 CET
- NHS contract: Maximum value of 330 million pounds; current arrangement through March 2029
